Latest & greatest articles for azithromycin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on azithromycin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on azithromycin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for azithromycin

81. Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis

Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis Magid D, Douglas J, Schwartz S Record Status (...) . Doxycycline compared with azithromycin for treating women with genital Chlamydia trachomatis infections: an incremental cost-effectiveness analysis. Annals of Internal Medicine 1996; 124(4): 389-399 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Analysis of Variance; Azithromycin /administration & Chlamydia Infections /drug therapy /economics; Chlamydia trachomatis; Cost-Benefit Analysis; Decision Trees; Doxycycline /administration & Drug Administration Schedule; Female; Genital Diseases

1996 NHS Economic Evaluation Database.

82. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin

Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin Carbon C, Hotton J M, Pepin L F, Wohlhuter C, Souetre E, Hardens M, Lozet H, Riviera (...) M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Azithromycin vs roxithromycin for the treatment of beta-haemolytic streptococcal pharyngitis. Type of intervention Secondary prevention. Economic study type Cost-effectiveness

1996 NHS Economic Evaluation Database.

83. Effects of azithromycin on malariometric indices in The Gambia. (PubMed)

Effects of azithromycin on malariometric indices in The Gambia. Azithromycin (a macrolide-like antibiotic) has antimalarial effects in vitro and in animal models. In the course of a randomised trial of trachoma control we examined the effects of azithromycin on parasite and spleen rates in the population aged 5-14 years from eight villages in the Farafenni study area in The Gambia, West Africa. The entire population of four treatment villages received three doses of azithromycin 20 mg/kg weekly (...) (days 1, 8, and 15) and four control villages received daily tetracycline eye ointment topically (days 1-42). Among 226 children studied before treatment and at day 28, azithromycin reduced the proportions with Plasmodium falciparum parasites (rate ratio 0.56, 95% confidence interval 0.44-0.71; p < 0.0001), with palpable spleens (RR 0.50, 95% CI 0.36-0.70; p < 0.0001), with febrile parasitaemia (RR 0.45, 95% CI 0.27-0.75; p < 0.01), and with P malariae infection (p < 0.001). This effect was related

1995 Lancet

84. Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. (PubMed)

Azithromycin for empirical treatment of the nongonococcal urethritis syndrome in men. A randomized double-blind study. To evaluate the use of single-dose azithromycin for empirical treatment of nongonococcal urethritis.Randomized, double-blind, multicenter trial comparing azithromycin vs doxycycline therapy, with a 2:1 randomization ratio. Patients were evaluated clinically and microbiologically for Chlamydia trachomatis and Ureaplasma urealyticum infection before therapy and at 2 and 5 weeks (...) after study entry.Eleven sexually transmitted disease clinics throughout the United States.A total of 452 men aged 18 years or older with symptomatic nongonococcal urethritis of less than 14 days' duration.Patients were treated with either 1.0 g of azithromycin as a single oral dose or 100 mg of doxycycline taken orally twice daily for 7 days.Clinical resolution of symptoms and signs of nongonococcal urethritis, microbiological cure of C trachomatis and U urealyticum, and occurrence of adverse

1995 JAMA

85. Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study

Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study Azithromycin compared with clarithromycin in the treatment of patients with acute purulent tracheobronchitis: a cost of illness study Sternon J, Leclerq P, Knepper C, Blot K Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Azithromycin or clarithromycin in the treatment of acute purulent tracheobronchitis in adult patients. Clarithromycin (250mg twice daily) was given for 7 to 10 days. Azithromycin was given for 3 days (500mg once daily) or5 days (500mg once daily

1995 NHS Economic Evaluation Database.

86. The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women

The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women The cost effectiveness of azithromycin for Chlamydia trachomatis infections in women Haddix A C, Hillis S D, Kassler W J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Azithromycin and doxycycline in the treatment of cervical chlamydia infections. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population A hypothetical cohort of 10,000 women with clinically suspected genital Chlamydia trachomatis and a cohort of 10,000 women with laboratory confirmed Chlamydia trachomatis. Pregnant women were excluded since

1995 NHS Economic Evaluation Database.

87. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. (PubMed)

Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Blindness due to trachoma is a serious public health issue world wide. The currently recommended treatment of active trachoma with repeated doses of tetracycline eye ointment has many disadvantages. The new azalide antibiotic azithromycin is effective as a single oral dose in the chemotherapy of genital Chlamydia trachomatis infections, and we have assessed its efficacy for trachoma treatment. We carried out (...) a randomised single-blind comparison of azithromycin (a single oral dose of 20 mg/kg) with conventional treatment (6 weeks of topical tetracycline plus erythromycin for severe cases) in two villages with endemic trachoma in The Gambia. The patients were followed up for 26 weeks from the start of treatment by an observer unaware of treatment allocation. By 6 months' follow-up, trachoma had resolved in 76 (78%) of 97 subjects who received azithromycin compared with 70 (72%) of 97 who were treated

1993 Lancet

88. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. (PubMed)

A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis. The Azithromycin for Chlamydial Infections Study Group. Currently, there is no single-dose therapy that is effective in the treatment of urethral or endocervical infections with Chlamydia trachomatis. Azithromycin is a new azalide antibiotic that has substantial activity against C. trachomatis, is concentrated intracellularly, and has a long half-life in serum and tissue.We conducted (...) a trial in which 299 female patients and 158 male patients with uncomplicated genital infection and a positive C. trachomatis antigen test were randomly assigned to receive either azithromycin (1 g once orally) or doxycycline (100 mg orally twice daily for seven days). Only patients subsequently determined to have a culture positive for C. trachomatis at base line were included in the evaluation of efficacy.Among the patients who could be evaluated, 5 of the 141 patients (4 percent) treated

1992 NEJM